Bifeprunox FDA Approval Status
Bifeprunox is an investigational atypical antipsychotic for the treatment of schizophrenia.
In August 2007, Wyeth Pharmaceuticals and Solvay Pharmaceuticals, Inc. announced the receipt of a Not Approvable Letter from the FDA advising the companies that the New Drug Application (NDA) for bifeprunox had not been approved.
Development timeline for Bifeprunox
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.